A double-blind, placebo-controlled study with oxiracetam in demented patients administered the Luria-Nebraska Neuropsychological Battery

A. Mangoni, C. Perin, S. Smirne, I. Piccolo, F. De Filippi, C. Marchetti, A. Motta, G. C. Monza

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A formal multicenter, double-blind, between-patient trial was carried out to evaluate the efficacy and tolerability of oxiracetam (OXIR) (800-mg tablets), in comparison with placebo, each given twice daily for 24 weeks to patients suffering from probable or possible Alzheimer's disease (AD). Efficacy was assessed by the Inventory of Psychic and Somatic Complaints in the Elderly (IPSC-E), administered at entry and after 8, 16, and 24 weeks of treatment, and by the Luria-Nebraska Neuropsychological Battery (LNNB), administered at the beginning and at the end of the study. Thirty patients (16 on OXIR and 14 on placebo), 20 males and 10 females, mean age 62 years (range 52-79), were enrolled and completed the study. A significant (P <0.01) difference between treatments in the total score of the IPSC-E, as well as in some LNNB scales, was observed. In particular, patients on OXIR showed an improvement over time, while the condition of patients on placebo remained unchanged or tended to get worse. No difference in tolerability between the active drug and placebo was observed.

Original languageEnglish
Pages (from-to)217-222
Number of pages6
JournalDrug Development Research
Volume14
Issue number3-4
Publication statusPublished - 1988

Fingerprint

Luria-Nebraska Neuropsychological Battery
Placebos
Tablets
Equipment and Supplies
Alzheimer Disease
Pharmaceutical Preparations
oxiracetam
Therapeutics

ASJC Scopus subject areas

  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Cite this

A double-blind, placebo-controlled study with oxiracetam in demented patients administered the Luria-Nebraska Neuropsychological Battery. / Mangoni, A.; Perin, C.; Smirne, S.; Piccolo, I.; De Filippi, F.; Marchetti, C.; Motta, A.; Monza, G. C.

In: Drug Development Research, Vol. 14, No. 3-4, 1988, p. 217-222.

Research output: Contribution to journalArticle

Mangoni, A, Perin, C, Smirne, S, Piccolo, I, De Filippi, F, Marchetti, C, Motta, A & Monza, GC 1988, 'A double-blind, placebo-controlled study with oxiracetam in demented patients administered the Luria-Nebraska Neuropsychological Battery', Drug Development Research, vol. 14, no. 3-4, pp. 217-222.
Mangoni, A. ; Perin, C. ; Smirne, S. ; Piccolo, I. ; De Filippi, F. ; Marchetti, C. ; Motta, A. ; Monza, G. C. / A double-blind, placebo-controlled study with oxiracetam in demented patients administered the Luria-Nebraska Neuropsychological Battery. In: Drug Development Research. 1988 ; Vol. 14, No. 3-4. pp. 217-222.
@article{5720146caac4481784f25e25b7bfb173,
title = "A double-blind, placebo-controlled study with oxiracetam in demented patients administered the Luria-Nebraska Neuropsychological Battery",
abstract = "A formal multicenter, double-blind, between-patient trial was carried out to evaluate the efficacy and tolerability of oxiracetam (OXIR) (800-mg tablets), in comparison with placebo, each given twice daily for 24 weeks to patients suffering from probable or possible Alzheimer's disease (AD). Efficacy was assessed by the Inventory of Psychic and Somatic Complaints in the Elderly (IPSC-E), administered at entry and after 8, 16, and 24 weeks of treatment, and by the Luria-Nebraska Neuropsychological Battery (LNNB), administered at the beginning and at the end of the study. Thirty patients (16 on OXIR and 14 on placebo), 20 males and 10 females, mean age 62 years (range 52-79), were enrolled and completed the study. A significant (P <0.01) difference between treatments in the total score of the IPSC-E, as well as in some LNNB scales, was observed. In particular, patients on OXIR showed an improvement over time, while the condition of patients on placebo remained unchanged or tended to get worse. No difference in tolerability between the active drug and placebo was observed.",
author = "A. Mangoni and C. Perin and S. Smirne and I. Piccolo and {De Filippi}, F. and C. Marchetti and A. Motta and Monza, {G. C.}",
year = "1988",
language = "English",
volume = "14",
pages = "217--222",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "3-4",

}

TY - JOUR

T1 - A double-blind, placebo-controlled study with oxiracetam in demented patients administered the Luria-Nebraska Neuropsychological Battery

AU - Mangoni, A.

AU - Perin, C.

AU - Smirne, S.

AU - Piccolo, I.

AU - De Filippi, F.

AU - Marchetti, C.

AU - Motta, A.

AU - Monza, G. C.

PY - 1988

Y1 - 1988

N2 - A formal multicenter, double-blind, between-patient trial was carried out to evaluate the efficacy and tolerability of oxiracetam (OXIR) (800-mg tablets), in comparison with placebo, each given twice daily for 24 weeks to patients suffering from probable or possible Alzheimer's disease (AD). Efficacy was assessed by the Inventory of Psychic and Somatic Complaints in the Elderly (IPSC-E), administered at entry and after 8, 16, and 24 weeks of treatment, and by the Luria-Nebraska Neuropsychological Battery (LNNB), administered at the beginning and at the end of the study. Thirty patients (16 on OXIR and 14 on placebo), 20 males and 10 females, mean age 62 years (range 52-79), were enrolled and completed the study. A significant (P <0.01) difference between treatments in the total score of the IPSC-E, as well as in some LNNB scales, was observed. In particular, patients on OXIR showed an improvement over time, while the condition of patients on placebo remained unchanged or tended to get worse. No difference in tolerability between the active drug and placebo was observed.

AB - A formal multicenter, double-blind, between-patient trial was carried out to evaluate the efficacy and tolerability of oxiracetam (OXIR) (800-mg tablets), in comparison with placebo, each given twice daily for 24 weeks to patients suffering from probable or possible Alzheimer's disease (AD). Efficacy was assessed by the Inventory of Psychic and Somatic Complaints in the Elderly (IPSC-E), administered at entry and after 8, 16, and 24 weeks of treatment, and by the Luria-Nebraska Neuropsychological Battery (LNNB), administered at the beginning and at the end of the study. Thirty patients (16 on OXIR and 14 on placebo), 20 males and 10 females, mean age 62 years (range 52-79), were enrolled and completed the study. A significant (P <0.01) difference between treatments in the total score of the IPSC-E, as well as in some LNNB scales, was observed. In particular, patients on OXIR showed an improvement over time, while the condition of patients on placebo remained unchanged or tended to get worse. No difference in tolerability between the active drug and placebo was observed.

UR - http://www.scopus.com/inward/record.url?scp=0024152789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024152789&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0024152789

VL - 14

SP - 217

EP - 222

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 3-4

ER -